TUBERCULOSIS SECOND LINE KIT (10 Slants)

Tuberculosis Second Line Kit consists of seven antitubercular drug slants Kanamycin, Amikacin, Ethionamide, D-Cycloserine, Clarithromycin, Ciprofloxacin, and p-Amino salicylic acid along with three controls to analyze the drug susceptibility pattern of Mycobacterium tuberculosis. The kit is designed to aid in the detection of resistance to some second-line antitubercular drugs through in-vitro susceptibility testing.
Resistance to one or more antitubercular drugs complicates tuberculosis treatment and may result from improper treatment regimens or incomplete therapy. In-vitro susceptibility testing gives data on the pattern of sensitivity of M. tuberculosis strain to individual drugs which informs the laboratory testing for drug resistance.
The susceptibility testing can be carried out on either a decontaminated and concentrated smear-positive sputum sample or a pure culture of Mycobacteria obtained from a clinical sample. The direct test may yield the results earlier, usually in 3-4 weeks, whereas indirect testing may take approximately 5-7 weeks.
Each drug-containing slant enables testing of the pathogen against a particular second-line agent, and the included controls permit proper evaluation of the test. All work with Mycobacteria cultures and clinical specimens should be conducted in accordance with appropriate biosafety practices and local laboratory procedures.

Provides a second-line tuberculosis drug susceptibility panel for assessing M. tuberculosis resistance against seven antitubercular agents.